

September 16, 2024

To The Corporate Relations Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Code: 540222	To The Listing Department National Stock Exchange of India Ltd., Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051 Code: LAURUSLABS
---	---

Dear Sir / Madam,

Sub: Press Release - Laurus Labs inaugurates new State of the Art R&D facility at IKP Knowledge Park

We enclose a copy of the Press Release that is being issued by the Company in connection with inauguration of a new Research and Development facility at IKP Knowledge Park.

Please take the above information on record.

Yours faithfully,

For **Laurus Labs Limited**

G. Venkateswar Reddy
Company Secretary & Compliance Officer

Encl: A/a

Registered Office

Laurus Enclave, Plot Office 01, E. Bonangi Village,
Parawada Mandal, Anapalli District - 531021, Andhra Pradesh, India.

T +91 891 682 1101, 1102, **E** info@lauruslabs.com
F +91 891 682 1103, **W** lauruslabs.com

CIN : L24239AP2005PLC047518,

Corporate Office

2nd Floor, SDE Serene Chambers, Road No. 7,
Banjara Hills, Hyderabad - 500034, Telangana, India.

T +91 40 6659 4333, 3980 4333, 2342 0500 / 501,
F +91 40 6659 4320 / 3980 4320

Investors Relations

Vivek Kumar
+91 40 3980 4366
investorrelations@lauruslabs.com

Media Relations

Karthik C
+91 40 3980 4380 | 9030088669
mediarelations@lauruslabs.com

Press Release

FOR IMMEDIATE RELEASE

16 SEPTEMBER, 2024

Laurus Labs Inaugurates New State of the Art R&D Facility at IKP Knowledge Park

Hyderabad, September 16, 2024: Laurus Labs Ltd. (Laurus BSE: 540222, NSE: LAURUSLABS, ISIN: INE947Q01028), a leading research and development driven pharmaceutical and biotech company in India is pleased to announce the inauguration of its state of the art new R&D center at IKP Knowledge Park, Plot No DS15, Kolthur Shamirpet Medchal Telangana. The facility was inaugurated by Honourable Shri Duddilla Sridhar Babu Garu, Minister of Information Technology, Electronics & Communications, Industries & Commerce and Legislative Affairs – Government of Telangana along with Dr.Satyanarayana Chava, Founder & CEO Laurus Labs along with other senior management team. The cutting edge facility is designed to foster innovation & advance the company's mission developing 'Chemistry for Better Living'.

On the occasion of the inauguration *Dr.Satyanarayana Chava, Founder & CEO Laurus Labs*, said "This will be our 5th R&D center and the new R&D center will be a testimonial to our commitment to innovation and excellence. We believe that this facility will enable us to develop ground breaking solutions that will address unmet medical needs".

Key highlights

- Total investment incurred for setting up the new R&D Rs 250 Cr
- 2,00,000 Square foot facility equipped with modern laboratories and infrastructure
- R&D Center to support the CDMO business of Laurus Labs
- Will provide job opportunities to over 800 people

END

Corporate Office

2nd Floor, Serene Chambers, Road No.7, Banjara Hills, Hyderabad 500034, Telangana, India
T +91 40 6659 4333, 3980 4333, 2342 0500/501 F +91 40 6659 4320 / 3980 4320

Registered Office

Laurus Enclave, Plot Office 01, E.Bonangi Village, Parawada Mandal, Anakapalli District – 531021, Andra Pradesh, India
CIN : L24239AP2005PLC047518, T +91 891 682 1101, 1102, F +91 891 682 1103, E info@lauruslabs.com, W lauruslabs.com

About Laurus Labs

Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company with an aim to improve the quality of life for millions of people around the world. Laurus has a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (incl High Potent APIs), Cardiovascular, and Gastro therapeutics. Laurus also offers integrated Contract Development and Manufacturing Organization (CDMO) services to Global Innovators from Clinical phase drug development to commercial manufacturing. Laurus is passionate about continuous technological advances for Smart and Green chemistry technologies to drive efficiencies and sustainable manufacturing backed by proven regulatory and quality foundation. Laurus employs 6500+ people, including around 1250+ scientists at more than 11 facilities approved by global agencies USFDA, WHO-Geneva, Japan-PDMA, UK-MHRA, EMA, TGA etc. During FY2023 Laurus generated ₹ 6,041 crore in annual revenue and is listed on the BSE (Bombay Stock Exchange) and the NSE (National Stock Exchange) in India. Laurus' proactive stance to conduct business with utmost Transparency, Integrity and Respect for environment & communities have earned it a place in Governance benchmark, consistently Certified Great Place to Work and Rated "BBB" by leading MSCI ESG Ratings. Corporate Identification No: L24239AP2005PLC047518.

For more information visit www.lauruslabs.com

Disclaimer

Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Laurus Labs Limited (Laurus) will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.